Aug. 13 at 5:58 PM
$MODD Embecta said they didn’t want to spend any more money developing the pump, which was costing like
$70 million a year in R&D. But, the rest of their business is just pens and syringes, and the stock has gone straight down since. They have a huge pile of debt, but they still make good money. Seems strange to just abandon the only potential growth program they had, even if it required a lot more money. As I said, my guess is Insulet had them dead to rights on patents.
